Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways

Journal of Pineal Research

Volumn 51, Issue 2, 2011, Pages 187-194

  Park, Ki Ho ^a   Kang, Jong Won ^a   Lee, Eun Man ^a   Kim, Jae Sik ^a   Rhee, Yun Hee ^a   Kim, Minseok ^b   Jeong, Soo Jin ^a   Park, Young Guk ^a   Hoon Kim, Sung ^a  

^a Kyung Hee University   (South Korea)

^b TUFTS UNIVERSITY SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

catenin; bone morphogenic protein; extracellular signal regulated kinase; melatonin; osteoblastic differentiation; Wnt

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; BETA CATENIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; GLYCOGEN SYNTHASE KINASE 3BETA; MELATONIN; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCALCIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RUNX2; WNT PROTEIN;

ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL STRAIN MC3T3 E1; CONFOCAL MICROSCOPY; CONTROLLED STUDY; MOUSE; NONHUMAN; OSTEOBLAST; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WOUND HEALING;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ANTIOXIDANTS; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; CALCIFICATION, PHYSIOLOGIC; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; CELL NUCLEUS; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; GLYCOGEN SYNTHASE KINASE 3; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MELATONIN; MICE; OSTEOBLASTS; OSTEOCALCIN; TIME FACTORS; WNT PROTEINS; WOUND HEALING;

EID: 80051670158     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2011.00875.x     Document Type: Article

References (55)

1. Ducy P, Schinke T, Karsenty G,. The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000; 289: 1501-1504.
2. Harada S, Rodan GA,. Control of osteoblast function and regulation of bone mass. Nature 2003; 423: 349-355. (Pubitemid 40852710)
3. Teitelbaum SL, Ross FP,. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003; 4: 638-649. (Pubitemid 36917505)
4. Wozney JM, Rosen V, Celeste AJ, et al., Novel regulators of bone formation: molecular clones and activities. Science 1988; 242: 1528-1534. (Pubitemid 19023695)
5. Tsuji K, Bandyopadhyay A, Harfe BD, et al., BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet 2006; 38: 1424-1429. (Pubitemid 44837565)
6. Fleet JC, Cashman K, Cox K, et al., The effects of aging on the bone inductive activity of recombinant human bone morphogenetic protein-2. Endocrinology 1996; 137: 4605-4610. (Pubitemid 26403295)
7. Meyer RA Jr, Meyer MH, Tenholder M, et al., Gene expression in older rats with delayed union of femoral fractures. J Bone Joint Surg Am 2003; 85-A: 1243-1254. (Pubitemid 36764932)
8. Styrkarsdottir U, Cazier JB, Kong A, et al., Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biol 2003; 1: E69.
9. Cassone VM,. Effects of melatonin on vertebrate circadian systems. Trends Neurosci 1990; 13: 457-464. (Pubitemid 20332799)
10. Reiter RJ, Tan DX, Manchester LC, et al., Melatonin and reproduction revisited. Biol Reprod 2009; 81: 445-456.
11. Reiter RJ, Tan DX, Fuentes-Broto L,. Melatonin: a multitasking molecule. Prog Brain Res 2010; 181: 127-151.
12. Tan DX, Chen LD, Poeggeler BEA,. Melatonin: a potent, endogenous hydroxyl radical scavenger. Endocr J 1993; 1: 57-60.
13. Paradies G, Petrosillo G, Paradies V, et al., Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48: 297-310.
14. Chahbouni M, Escames G, Venegas C, et al., Melatonin treatment normalizes plasma pro-inflammatory cytokines and nitrosative/oxidative stress in patients suffering from Duchenne muscular dystrophy. J Pineal Res 2010; 48: 282-289.
15. Dominguez-Rodriguez A, Abreu-Gonzalez P, Sanchez-Sanchez JJ, et al., Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 2010; 49: 14-22.
16. Reiter RJ, Tan DX, Paredes SD, et al., Beneficial effects of melatonin in cardiovascular disease. Ann Med 2010; 42: 276-285.
17. Zhang L, Su P, Xu C, et al., Melatonin inhibits adipogenesis and enhances osteogenesis of human mesenchymal stem cells by suppressing PPARgamma expression and enhancing Runx2 expression. J Pineal Res 2010; 49: 364-372.
18. Sethi S, Radio NM, Kotlarczyk MP, et al., Determination of the minimal melatonin exposure required to induce osteoblast differentiation from human mesenchymal stem cells and these effects on downstream signaling pathways. J Pineal Res 2010; 49: 222-238.
19. Calvo-Guirado JL, Gomez-Moreno G, Lopez-Mari L, et al., Actions of melatonin mixed with collagenized porcine bone versus porcine bone only on osteointegration of dental implants. J Pineal Res 2010; 48: 194-203.
20. Calvo-Guirado JL, Gomez-Moreno G, Barone A, et al., Melatonin plus porcine bone on discrete calcium deposit implant surface stimulates osteointegration in dental implants. J Pineal Res 2009; 47: 164-172.
21. Park KH, Han DI, Rhee YH, et al., Protein kinase C betaII and delta/theta play critical roles in bone morphogenic protein-4-stimulated osteoblastic differentiation of MC3T3-E1 cells. Biochem Biophys Res Commun 2010; 403: 7-12.
22. Ariffin SH, Abidin IZ, Yazid MD, et al., Differentiation analyses of adult suspension mononucleated peripheral blood cells of Mus musculus. Cell Commun Signal 2010; 8: 29.
23. Reddi AH,. Bone and cartilage differentiation. Curr Opin Genet Dev 1994; 4: 737-744. (Pubitemid 24322911)
24. Lowry OH, Roberts NR, Wu ML, et al., The quantitative histochemistry of brain. II. Enzyme measurements. J Biol Chem 1954; 207: 19-37.
25. Tang CH, Lu DY, Tan TW, et al., Ultrasound induces hypoxia-inducible factor-1 activation and inducible nitric-oxide synthase expression through the integrin/integrin-linked kinase/Akt/mammalian target of rapamycin pathway in osteoblasts. J Biol Chem 2007; 282: 25406-25415.
26. Wu JB, Fong YC, Tsai HY, et al., Naringin-induced bone morphogenetic protein-2 expression via PI3K, Akt, c-Fos/c-Jun and AP-1 pathway in osteoblasts. Eur J Pharmacol 2008; 588: 333-341.
27. Garrett IR, Chen D, Gutierrez G, et al., Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003; 111: 1771-1782. (Pubitemid 38057757)
28. Knosp WM, Scott V, Bachinger HP, et al., HOXA13 regulates the expression of bone morphogenetic proteins 2 and 7 to control distal limb morphogenesis. Development 2004; 131: 4581-4592. (Pubitemid 39409698)
29. Virdi AS, Cook LJ, Oreffo RO, et al., Modulation of bone morphogenetic protein-2 and bone morphogenetic protein-4 gene expression in osteoblastic cell lines. Cell Mol Biol (Noisy-le-grand) 1998; 44: 1237-1246.
30. Willert K, Jones KA,. Wnt signaling: is the party in the nucleus? Genes Dev 2006; 20: 1394-1404. (Pubitemid 43830647)
31. Yamaguchi A, Komori T, Suda T,. Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. Endocr Rev 2000; 21: 393-411. (Pubitemid 32275586)
32. Komori T,. Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 2010; 339: 189-195.
33. Wada S, Fukawa T, Kamiya S,. [Osteocalcin and bone]. Clin Calcium 2007; 17: 1673-1677.
34. Kirker-Head CA, Boudrieau RJ, Kraus KH,. Use of bone morphogenetic proteins for augmentation of bone regeneration. J Am Vet Med Assoc 2007; 231: 1039-1055. (Pubitemid 350013497)
35. Oshin AO, Stewart MC,. The role of bone morphogenetic proteins in articular cartilage development, homeostasis and repair. Vet Comp Orthop Traumatol 2007; 20: 151-158. (Pubitemid 47328948)
36. Baron R, Rawadi G, Roman-Roman S,. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol 2006; 76: 103-127. (Pubitemid 44760540)
37. Tamura M, Nemoto E, Sato MM, et al., Role of the Wnt signaling pathway in bone and tooth. Front Biosci (Elite Ed) 2010; 2: 1405-1413.
38. Bodine PV, Komm BS,. Wnt signaling and osteoblastogenesis. Rev Endocr Metab Disord 2006; 7: 33-39. (Pubitemid 46049520)
39. Filipenko NR, Attwell S, Roskelley C, et al., Integrin-linked kinase activity regulates Rac- and Cdc42-mediated actin cytoskeleton reorganization via alpha-PIX. Oncogene 2005; 24: 5837-5849. (Pubitemid 43080075)
40. Maier S, Lutz R, Gelman L, et al., Tenascin-C induction by cyclic strain requires integrin-linked kinase. Biochim Biophys Acta 2008; 1783: 1150-1162.
41. Chen Y, Du XY,. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem 2007; 100: 1337-1345. (Pubitemid 46515568)
42. Cortizo AM, Lettieri MG, Barrio DA, et al., Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK). Mol Cell Biochem 2003; 250: 1-10. (Pubitemid 37045717)
43. Jaiswal RK, Jaiswal N, Bruder SP, et al., Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. J Biol Chem 2000; 275: 9645-9652. (Pubitemid 30185197)
44. Naor Z, Benard O, Seger R,. Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab 2000; 11: 91-99. (Pubitemid 30165715)
45. Rodriguez JP, Rios S, Fernandez M, et al., Differential activation of ERK1,2 MAP kinase signaling pathway in mesenchymal stem cell from control and osteoporotic postmenopausal women. J Cell Biochem 2004; 92: 745-754. (Pubitemid 44264265)
46. Vinals F, Lopez-Rovira T, Rosa JL, et al., Inhibition of PI3K/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett 2002; 510: 99-104. (Pubitemid 34084891)
47. Chen D, Zhao M, Mundy GR,. Bone morphogenetic proteins. Growth Factors 2004; 22: 233-241. (Pubitemid 40136452)
48. Parisi MS, Gazzerro E, Rydziel S, et al., Expression and regulation of CCN genes in murine osteoblasts. Bone 2006; 38: 671-677.
49. Sykaras N, Opperman LA,. Bone morphogenetic proteins (BMPs): how do they function and what can they offer the clinician? J Oral Sci 2003; 45: 57-73.
50. Semenov M, Tamai K, He X,. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J Biol Chem 2005; 280: 26770-26775. (Pubitemid 41040710)
51. Winkler DG, Sutherland MK, Geoghegan JC, et al., Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 2003; 22: 6267-6276. (Pubitemid 37522584)
52. Li X, Zhang Y, Kang H, et al., Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005; 280: 19883-19887. (Pubitemid 41379516)
53. Winkler DG, Sutherland MS, Ojala E, et al., Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 2005; 280: 2498-2502. (Pubitemid 40189350)
54. Craig TA, Bhattacharya R, Mukhopadhyay D, et al., Sclerostin binds and regulates the activity of cysteine-rich protein 61. Biochem Biophys Res Commun 2010; 392: 36-40.
55. Suzuki A, Palmer G, Bonjour JP, et al., Regulation of alkaline phosphatase activity by p38 MAP kinase in response to activation of Gi protein-coupled receptors by epinephrine in osteoblast-like cells. Endocrinology 1999; 140: 3177-3182. (Pubitemid 30650634)